Literature DB >> 14733847

Yellow Fever Immunizations: Indications and Risks.

Mary E. Wilson1, Lin H. Chen, Elizabeth D. Barnett.   

Abstract

The yellow fever vaccine plays an essential role in protecting humans from yellow fever, and millions of doses are administered each year. The attenuated live-virus vaccine has long been considered to be among the safest and most effective vaccines. Newly recognized rare, but sometimes fatal, adverse events associated with the vaccine have prompted scrutiny of the traditional recommendations for use of the vaccine and have raised questions about their pathogenesis. This paper describes the adverse events associated with the vaccine, reviews postulated reasons for the recent recognition of these events, discusses key research questions that need to be addressed in trying to understand their origin and risk factors, and reviews current indications for the use of the vaccine. Knowledge of the epidemiology of yellow fever is necessary to make informed recommendations. Current surveillance is inadequate to provide a precise exposure risk for most travelers.

Entities:  

Year:  2004        PMID: 14733847     DOI: 10.1007/s11908-004-0022-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  40 in total

1.  Yellow fever, 1998-1999.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2000-10-06

Review 2.  Prevention of yellow fever in persons traveling to the tropics.

Authors:  Thomas P Monath; Martin S Cetron
Journal:  Clin Infect Dis       Date:  2002-04-25       Impact factor: 9.079

3.  Jungle yellow fever in the central Amazon.

Authors:  M L Barros; G Boecken
Journal:  Lancet       Date:  1996-10-05       Impact factor: 79.321

4.  Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

Authors:  R C Chan; D J Penney; D Little; I W Carter; J A Roberts; W D Rawlinson
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

5.  Urbanisation of yellow fever in Santa Cruz, Bolivia.

Authors:  P Van der Stuyft; A Gianella; M Pirard; J Cespedes; J Lora; C Peredo; J L Pelegrino; V Vorndam; M Boelaert
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

6.  Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-08-03       Impact factor: 17.586

7.  Outbreak of jaundice and hemorrhagic fever in the Southeast of Brazil in 2001: detection and molecular characterization of yellow fever virus.

Authors:  A M B de Filippis; R M R Nogueira; H G Schatzmayr; D S Tavares; A V Jabor; S C M Diniz; J C Oliveira; E Moreira; M P Miagostovich; E V Costa; R Galler
Journal:  J Med Virol       Date:  2002-12       Impact factor: 2.327

8.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

9.  Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide.

Authors:  T P Monath; R M Kinney; J J Schlesinger; M W Brandriss; P Brès
Journal:  J Gen Virol       Date:  1983-03       Impact factor: 3.891

10.  Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.

Authors:  Kitisak Kengsakul; Kriengkrai Sathirapongsasuti; Sompone Punyagupta
Journal:  J Med Assoc Thai       Date:  2002-01
View more
  2 in total

Review 1.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

2.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.